💉 Moderna: People’s Lives Or Sales? UBER crashes on rising costs. PayPal rips post earnings.

UBER crashes on rising costs. PayPal rips post earnings.

Hey Global Investor, here’s what you need to know before the US markets open.

Market Snapshot 📈

S&P 500 (Wednesday’s Close) 4,167.59 +2.93 (0.07%)

NASDAQ (Wednesday’s Close) 13,582.42 -51.08 (0.37%)

FTSE 100 (5 PM IST) 7,049.85 +10.55 (0.15%)

NIFTY 50 (Today’s Close) 14,724.8 +106.95 (0.73%)

USDINR (5 PM IST) 73.73 (1 Year -2.71%)

🔥 Top Movers

HNST +43.75%
HAYW +24.34%
FDP +19.99%

INTZ -28.82%
ESPA -21.81%
STX -21.81%

💉 Moderna: People’s Lives Or Sales?

The US government is finally supporting a waiver of intellectual property protection for Covid-19 vaccines. Such a waiver would put at risk the multi-billion dollar sales of vaccine manufacturers such as Moderna (MRNA). No wonder they’re vehemently opposing this move. (Tweet This)

The Patent Roadblock
With over 150M cases and 3.2M deaths worldwide, Covid-19 has been among the worst global health crises in history. Incredibly enough, researchers managed to create vaccines that have a high effectivity rate against the virus. This wouldn’t have happened without ample help from governments around the world that approved the emergency authorization of these vaccines.

Thus far, over 1.2B doses have been administered globally. Just as confidence was growing in the vaccines’ efficacy, new mutations of the virus have played havoc. India seems to be bearing the brunt of this surge with more than 400K cases being reported on a daily basis.  Back in October, India and South Africa appealed to the WTO to suspend vaccine patents. This proposal was in keeping with the greater good of the billions of people that were at risk in the developing world. More than 100 countries supported but were met with opposition from – you guessed it right – the US and the EU. The innovator pharma companies are protected by intellectual property laws and in effect have a monopoly on the production, distribution, and pricing of the medication in question – in this case, the vaccine.

Not There Yet
A look at the quantum of sales these vaccines represent tells you why the pharma companies are singularly opposed to waiving the patent protections. Moderna expects $18.5B in sales from the vaccine while Pfizer expects $15B. They’re fighting syringe-and-needle to maintain the status quo.

The WHO also came out in favor of the waiver that India was seeking. India is a global powerhouse in generic medicine manufacturing. Easing of the patent rights will allow Indian manufacturers to produce the vaccine at a fraction of the cost and distribute it widely around the world for use. Worries that the fast-mutating virus will bring the fledgling economic recovery to a halt put the Biden administration under intense pressure to support the waiver. Finally, yesterday, the White House signaled it’s amenable to changing the rules. However, this won’t happen overnight. The WTO will need consensus from all 164 member nations to implement the waiver. There are enough corporate lobbyists and vested interests that want to scuttle any consensus on this issue. One of the biggest losers, in this case, will be Moderna whose vaccine has a 96% effective rate with almost no side effects. It remains to be seen whether altruism will trump capitalism.Market Reaction
MRNA ended the day at $162.84, down 6.19%.

Company Snapshot 📈

MRNA $162.84 -10.75 (6.19%)

Analyst Ratings (17 Analysts) BUY 47%  HOLD 29%  SELL 24%


Newsworthy 📰

Expenses: Uber sees driver cost rising as U.S. economy recovers (UBER -3.42%)

Digital $: PayPal profit tops estimates on digital payments boom (PYPL -1.10%)

Burden: FedEx to reduce debt by $2.6 billion after bond offering (FDX +0.74%)

Later Today 🕒

  • Volkswagen Earnings (VLKAF)
  • Linde Plc Earnings (LIN)
  • Square Earnings (SQ)
  • 6:00 PM IST: Initial Jobless Claims
  • 1:30 AM IST: Fed Releases Financial Stability Report

Fun Fact of The Day 🌞

The creator and designer of the famous Nike swoosh tick was paid $35

Disclaimer: The content of this article has been created and published by Winvesta India Technologies Pvt. Ltd., in order to ease the reader’s understanding of the subject matter. The information and/or content (collectively “Information”) provided herein is general information sourced through various news reports and does not constitute a research report or a research analysis. The Information is not intended to offer advice, target or solicit any particular customer or group of customers to buy or sell securities. 

Winvesta does not render any research or advisory services and provides a more detailed description of its services on its website and mobile application along with the terms and conditions published therein from time to time. While reasonable care has been exercised to ensure that the Information is adequate and reliable, no representation is made by Winvesta as to its accuracy or completeness and Winvesta, its affiliates, subsidiaries and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this Information. Neither Winvesta nor any of its affiliates are acting as an investment adviser, research analyst or in any other fiduciary capacity. Accordingly, reader’s are expected to undertake their own due diligence in consultation with their own advisors and are advised not to solely rely on the Information. Any such reliance shall be at the reader’s own risk. 

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing.

Start Building Your Global Portfolio Today

Download Winvesta App now to Get Started